Treatment outcomes and mortality of 94 patients with acromegaly

Due to new therapeutic modalities and modified therapeutic goals outcome of patients with acromegaly may change over time and differ by centre. We analysed treatment outcomes and mortality of our patients with acromegaly seen between 1971 and 2003. The cohort consisted of 94 patients who had been fo...

Full description

Saved in:
Bibliographic Details
Published in:Acta neurochirurgica 2005-03, Vol.147 (3), p.243-251
Main Authors: Trepp, R, Stettler, C, Zwahlen, M, Seiler, R, Diem, P, Christ, E R
Format: Article
Language:English
Subjects:
Acromegaly - etiology
Acromegaly - mortality
Acromegaly - therapy
Adenoma - mortality
Adenoma - pathology
Adenoma - therapy
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal - therapeutic use
Cohort Studies
Disease control
Drug Therapy - statistics & numerical data
Drug Therapy - trends
Female
Growth Hormone - blood
Growth Hormone - secretion
Humans
Male
Middle Aged
Mortality
Neoplasm Recurrence, Local - epidemiology
Neurosurgical Procedures - statistics & numerical data
Neurosurgical Procedures - trends
Octreotide - therapeutic use
Pituitary gland
Pituitary Gland - pathology
Pituitary Gland - physiopathology
Pituitary Gland - surgery
Pituitary Neoplasms - mortality
Pituitary Neoplasms - pathology
Pituitary Neoplasms - therapy
Radiation therapy
Radiotherapy - statistics & numerical data
Radiotherapy - trends
Remission Induction
Retrospective Studies
Sex Factors
Survival Rate
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to new therapeutic modalities and modified therapeutic goals outcome of patients with acromegaly may change over time and differ by centre. We analysed treatment outcomes and mortality of our patients with acromegaly seen between 1971 and 2003. The cohort consisted of 94 patients who had been followed for 0.3-31 years (mean 10.6 years). Remission criteria were a normalized IGF-I concentration, a nadir GH level during oral glucose load of
ISSN:0001-6268
0942-0940
DOI:10.1007/s00701-004-0466-2